Table 3. Key studies in first-line NSCLC.

Phase III study	Population	Treatment groups	HR, overall survival (m)
KEYNOTE-024	Untreated advanced NSCLC (no EGFR or ALK mutation) PD-L1 TPS _50%	Pembrolizumab versus Platinum-based chemotherapy	HR, 0.63 mOS, 30.0 months versus 14.2 months
KEYNOTE-042	Untreated locally advanced or metastatic NSCLC PD-L1 TPS_1%	Pembrolizumab versus Platinum-based chemotherapy	HR, 0.81 mOS, 16.7 months versus 12.1 months
KEYNOTE-189	Metastatic nonsquamous NSCLC (no EGFR or ALK mutation	Carboplatin/cisplatin pemetrexed pembrolizumab Carboplatin/cisplatin pemetrexed	HR, 0.49, 12-m OS, 69.2% versus 49.4%
KEYNOTE-407	Metastatic squamous NSCLC	Carboplatin/paclitaxel or nab-paclitaxel pembrolizumab Carboplatin/paclitaxel or nab-paclitaxel	HR, 0.64 mOS, 15.9 months versus 11.3 months
Checkmate 026	Stage IV or recurrent NSCLC PD-L1_1%	Nivolumab Platinum-based Chemotherapy	HR, 1.02 mOS, 14.4 months versus 13.2 months
Checkmate 227	Stage IV or recurrent NSCLC PD-L1 _1%	Nivolumab-ipilimumab versus Platinum-based chemotherapy	HR, 0.79 mOS, 17.1 months versus 14.9 months
IMpower 150	Metastatic nonsquamous NSCLC	Atezolizumab carboplatin/paclitaxel bevacizumab versus carboplatin/paclitaxel bevacizumab	HR, 0.78 mOS, 19.2 months versus 14.7 months
IMpower 110	Metastatic NSCLC (TC≥50% or IC≥10% stratified subgroup)	Atezolizumab versus cis/carboplatin pemetrexed (nonsquamous) or cis/carboplatin gemcitabine (squamous)	HR, 0,59 mOS 20.2 months versus 13.1 months